دورية أكاديمية
How Did Patients Living With Immune-Mediated Rheumatic Diseases Face the Beginning of the COVID-19 Pandemic in Brazil? Results of the COnVIDa Study.
العنوان: | How Did Patients Living With Immune-Mediated Rheumatic Diseases Face the Beginning of the COVID-19 Pandemic in Brazil? Results of the COnVIDa Study. |
---|---|
المؤلفون: | Pugliesi A; From the Reumatologia, Universidade Estadual de Campinas, Campinas., Sachetto Z; From the Reumatologia, Universidade Estadual de Campinas, Campinas., de Medeiros Pinheiro M; Reumatologia, Hospital São Paulo, Universidade Federal de São Paulo, São Paulo., Salviato Pileggi G; Reumatologia, Faculdade de Ciências da Saúde Barretos, Barretos, São Paulo., Sarot Pereira da Cunha G; Reumatologia, Universidade Federal do Paraná, Curitiba, Paraná., Hajar FN; Reumatologia, Universidade Federal do Paraná, Curitiba, Paraná., Marques Negrisolli Cunha ML; Reumatologia, Universidade Estadual do Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul., Henrique da Mota LM; Reumatologia, Universidade de Brasília, Brasília., Lopes Marques CD; Reumatologia, Universidade Federal de Pernambuco, Recife, Pernambuco., Kakehasi AM; Reumatologia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais., Rodrigues Ferreira WH; Reumatologia, Instituto Gruparj Petrópolis, Petrópolis, Rio de Janeiro., Araújo NC; Reumatologia, Hospital do Servidor Público Estadual de São Paulo-IAMSPE, São Paulo., Monteiro Gomides Reis AP; Reumatologia, Universidade de Brasília, Brasília., Rodrigues de Abreu Vieira RM; Reumatologia, Hospital Geral de Fortaleza, Ceará, Fortaleza., Ferreira GA; Reumatologia, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais., Danowski A; Reumatologia, Hospital Federal dos Servidores do Estado-RJ, Rio de Janeiro., de Souza VA; Reumatologia, Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais., Soares Egypto de Brito DC; Reumatologia, Universidade Federal da Paraíba, João Pessoa, Paraíba., Dos Santos Paiva E; Reumatologia, Faculdade de Medicina da Universidade Federal do Paraná, Santa Catarina, Paraná., Provenza JR; Reumatologia, Pontifícia Universidade Católica de Campinas, Campinas, São Paulo, Brazil., Feijó Azevedo V; Reumatologia, Faculdade de Medicina da Universidade Federal do Paraná, Santa Catarina, Paraná. |
المصدر: | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases [J Clin Rheumatol] 2024 Jan 01; Vol. 30 (1), pp. e29-e33. Date of Electronic Publication: 2022 Jun 14. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9518034 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1536-7355 (Electronic) Linking ISSN: 10761608 NLM ISO Abbreviation: J Clin Rheumatol Subsets: MEDLINE |
أسماء مطبوعة: | Publication: Philadelphia, PA : Lippincott Williams & Wilkins Original Publication: Baltimore, MD : Williams & Wilkins, c1995- |
مواضيع طبية MeSH: | COVID-19* , Rheumatic Diseases*/epidemiology, Humans ; Female ; Adult ; Middle Aged ; Brazil/epidemiology ; Pandemics ; Cross-Sectional Studies |
مستخلص: | Background: The coronavirus disease 2019 (COVID-19) pandemic has brought additional burden to patients living with immune-mediated rheumatic diseases (IMRDs), especially at the beginning of 2020, for which information for this population is lacking. Methods: COnVIDa is a cross-sectional study on patients with IMRD from all regions of Brazil who were invited to answer a specific and customized Web questionnaire about how they were facing the COVID-19 pandemic, especially focusing on health care access, use of medications, and patient-reported outcomes related to IMRD activity. The questionnaire was applied from June 1 to 30, 2020. Results: In total, 1722 of 2576 patients who answered the Web questionnaire were included in the final analysis. Participants were most frequently women, 56% were between 31 and 50 years old, and most (55%) has private health insurance. The most commonly reported IMRD was rheumatoid arthritis (39%), followed by systemic lupus erythematosus (28%). During the study period, 30.7% did not have access to rheumatology consultations, and 17.6% stopped chronic medications. Telemedicine was reported in 44.8% of patients. Conclusion: COnVIDa demonstrated a negative impact on health care access and treatment maintenance of patients living with IMRD during the COVID-19 pandemic. However, it also presented an uptake of telemedicine strategies. Data presented in this study may assist future coping policies. Competing Interests: The authors declare no conflict of interest. (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.) |
References: | Cevik M, Bamford CGG, Ho A. COVID-19 pandemic—a focused review for clinicians. Clin Microbiol Infect . 2020;26:842–847. doi:10.1016/j.cmi.2020.04.023. (PMID: 10.1016/j.cmi.2020.04.023) CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep . 2020;69:382–386. doi:10.15585/mmwr.mm6913e2. (PMID: 10.15585/mmwr.mm6913e2) World Health Organization. Coronavirus diseases 2019 (COVID-19) situation report—51. March 11, 2020. Cited June 24, 2020. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10 . Accessed January 11, 2021. Bugatti S, De Stefano L, Bobbio-Pallavicini F, et al. Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline. RMD Open . 2020;6:e001323. D’Silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’. Ann Rheum Dis . 2020;79:1156–1162. Haberman R, Axelrad J, Chen A, et al. COVID-19 in immune-mediated inflammatory diseases—case series from New York. N Engl J Med . 2020;383:85–88. Williamson EJ, Walker AJ, Bhaskaran K, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature . 2020;584:430–436. doi:10.1038/s41586-020-2521-4. (PMID: 10.1038/s41586-020-2521-4) Marques C, Pinheiro MM, Reis Neto ET, et al. COVID-19 in patients with rheumatic diseases: what is the real mortality risk? [published online July 13, 2020]. Ann Rheum Dis . 2020. doi:10.1136/annrheumdis-2020-218388. (PMID: 10.1136/annrheumdis-2020-218388) Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis . 2020;79:851–858. doi:10.1136/annrheumdis-2020-217877. COVID-19 clinical guidance for patients with rheumatic diseases. Developed by the ACR COVID-19 Clinical Guidance Task Force. (PMID: 10.1136/annrheumdis-2020-217877) Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 1. Arthritis Rheumatol . 2020;72:1241–1251. Michaud K, Wipfler K, Shaw Y, et al. Experiences of patients with rheumatic diseases in the United States during early days of the COVID-19 pandemic [published online April 4, 2021]. ACR Open Rheumatol . 2020;2:335–343. doi:10.1002/acr2.11148. (PMID: 10.1002/acr2.11148) Elera-Fitzcarrald C, Ugarte-Gil MF, Alarcón GS. COVID-19 and its potential effect on patients with rheumatic diseases in Latin America. J Clin Rheumatol . 2020;26:215–217. Candido DS, Claro IM, de Jesus JG, et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil. Science . 2020;369:1255–1260:epub ahead 2161. doi:10.1126/science.abd2161. (PMID: 10.1126/science.abd2161) Miethke-Morais A, Cassenote A, Piva H, et al. COVID-19–related hospital cost-outcome analysis: the impact of clinical and demographic factors. Braz J Infect Dis . 2021;25:101609. The impact of the COVID-19 pandemic on outpatient visits: changing patterns of care in the newest COVID-19 hot spots. August 13, 2020. Available at: https://www.commonwealthfund.org/publications/2020/aug/impact-covid-19-pandemic-outpatient-visits-changing-patterns-care-newest . Accessed January 5, 2021. Singh BSM, Chuah SL, Cheong YK, et al. Impact of lockdown on rheumatology outpatient care in the age of COVID-19 [published online August 7, 2020]. Ann Rheum Dis . 2020;annrheumdis-2020-218484. Guaracha-Basáñez GA, Contreras-Yáñez I, Hernández-Molina G, et al. Clinical and bioethical implications of health care interruption during the COVID-19 pandemic: a cross-sectional study in outpatients with rheumatic diseases. PLoS One . 2021;16:e0253718. Hammad MAH, Eissa M, Dawa GA. Impact of coronavirus disease 2019 (COVID-19) pandemic on attitude, behavior, and mental health of patients with rheumatic diseases. Egypt Rheumatol Rehabil . 2020;47:45. Hausmann JS, Kennedy K, Simard JF, et al. Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatol . 2021;3:e707–e714. Fragoulis GE, Evangelatos G, Arida A, et al. Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic [published online May 31, 2020]. Ann Rheum Dis . 2020;annrheumdis-2020-217935. Glintborg B, Jensen DV, Engel S, et al. Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry. RMD Open . 2021;7:e001505. Schmeiser T, Broll M, Dormann A, et al. A cross sectional study on patients with inflammatory rheumatic diseases in terms of their compliance to their immunsuppressive medication during COVID-19 pandemic. Z Rheumatol . 2020;1–6. Dharia T, Venkatachalam S, Baker JF, et al. Medication interruptions and subsequent disease flares during the COVID-19 pandemic: a longitudinal online study of patients with rheumatic disease. Arthritis Care Res (Hoboken) . 2021;74:733–740. Sparks JA, Wallace ZS, Seet AM, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance Physician Registry. Ann Rheum Dis . 2021;80:1137–1146. Bower H, Frisell T, Di Giuseppe D, et al. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Ann Rheum Dis . 2021;80:1086–1093. doi:10.1136/annrheumdis-2021-219845. (PMID: 10.1136/annrheumdis-2021-219845) Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol . 2021;3:e419–e426. Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19–related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry. Ann Rheum Dis . 2021;80:930–942. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry. Ann Rheum Dis . 2020;79:859–866. Marques CDL, Kakehasi AM, Pinheiro MM, et al. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. RMD Open . 2021;7:e001461. FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE Consortium and Contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis . 2020;80:527–538. doi:10.1136/annrheumdis-2020-218310. (PMID: 10.1136/annrheumdis-2020-218310) Kroon FPB, Najm A, Alunno A, et al. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. Ann Rheum Dis . 2021;81:422–432. doi:10.1136/annrheumdis-2021-221575. (PMID: 10.1136/annrheumdis-2021-221575) Ma MHY, Tay SH, Cheung PPM, et al. Attitudes and behaviors of patients with rheumatic diseases during the early stages of the COVID-19 outbreak. J Rheumatol . 2021;48:35–39. Doğan R, Kaplan Serin E, Bağci N. Fear of COVID 19 and social effects in liver transplant patients. Transpl Immunol . 2021;69:101479. Ciurea A, Papagiannoulis E, Bürki K, et al. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management Cohort. Ann Rheum Dis . 2021;80:238–241. Guaracha-Basáñez GA, Contreras-Yáñez I, Hernández-Molina G, et al. Quality of life of patients with rheumatic diseases during the COVID-19 pandemic: the biopsychosocial path. PLoS One . 2022;17:e0262756. Gıca Ş, Akkubak Y, Aksoy ZK, et al. Effects of the COVID-19 pandemic on psychology and disease activity in patients with ankylosing spondylitis and rheumatoid arthritis. Turk J Med Sci . 2021;51:1631–1639. Silva AB, da Silva RM, da Rocha Ribeiro G, et al. Three decades of telemedicine in Brazil: mapping the regulatory framework from 1990 to 2018. PLoS One . 2020;15:e0242869. Chisini LA, de Castilhos ED, Dos Santos Costa F, et al. Impact of the COVID-19 pandemic on prenatal, diabetes and medical appointments in the Brazilian National Health System. Rev Bras Epidemiol . 2021;24:e210013. Ferreira-Garcia R, Nascimento I. Telepsychiatry in Brazil during the COVID-19 pandemic: did we exchange a walk-on part in a war for a lead role in a cage? J Bras Psiquiatr . 2020;69:209–210. Carvalho CRR, Scudeller PG, Rabello G, et al. Use of telemedicine to combat the COVID-19 pandemic in Brazil. Clinics (Sao Paulo) . 2020;75:e2217. Cited March 21, 2022. Available at: http://www.scielo.br/j/clin/a/vtw8CxbHk8QgsfWP5NWwQmf/?lang=en . Accessed January 11, 2021. Ziadé N, El Kibbi L, Hmamouchi I, et al. Impact of the COVID-19 pandemic on patients with chronic rheumatic diseases: a study in 15 Arab countries. Int J Rheum Dis . 2020;23:1550–1557. Fernández-Ávila DG, Barahona-Correa J, Romero-Alvernia D, et al. Impact of COVID-19 pandemic on rheumatology practice in Latin America. J Rheumatol . 2021;48:1616–1622. Fontenelle LF, Sarti TD, Junqueira de Camargo MB, et al. Utilization of the Brazilian public health system by privately insured individuals: a literature review. Cad Saude Publica . 2019;35:e00004118. |
تواريخ الأحداث: | Date Created: 20220614 Date Completed: 20231222 Latest Revision: 20231222 |
رمز التحديث: | 20231222 |
DOI: | 10.1097/RHU.0000000000001882 |
PMID: | 35699528 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1536-7355 |
---|---|
DOI: | 10.1097/RHU.0000000000001882 |